Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : buys U.S. gene sequencing tech company Stratos Genomics

share with twitter share with LinkedIn share with facebook
share via e-mail
05/22/2020 | 01:24am EDT
Outbreak of the coronavirus disease (COVID-19) in Welwyn Garden City

Pharmaceutical group Roche has acquired U.S.-based Stratos Genomics to further develop DNA-based sequencing for diagnostic use, it said on Friday.

"The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion," the Swiss drug maker said in a statement. "The Roche nanopore sequencer, once developed, will utilise a novel approach that combines electronic and biological components to sequence DNA for fast, flexible and cost-effective clinical diagnostic testing."

Financial details of the agreement were not disclosed.

(Reporting by Brenna Hughes Neghaiwi; editing by Thomas Seythal)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING AG
06:13aCOMPULSORY LICENCES : The Key To Accessing Inventions In The Face Of Coronavirus..
AQ
05:00aROCHE : FDA approves Roche's Tecentriq in combination with Avastin for people wi..
AQ
01:00aFDA approves Roche's Tecentriq in combination with Avastin for people with th..
GL
06/01CHUGAI PHARMACEUTICAL : Obtains Approval for Expanded Use of FoundationOne CDx C..
AQ
06/01Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules against S..
AQ
06/01CHUGAI PHARMACEUTICAL : Updated Data of Overall Survival and Safety from the ALE..
AQ
06/01Chugai and FRONTEO Enter into a License Agreement for AI-based Drug Discovery..
AQ
06/01ROCHE HOLDINGS AG : Goldman Sachs gives a Buy rating
MD
05/29GENENTECH : FDA Approves Tecentriq in Combination With Avastin for Some Liver Ca..
DJ
05/29ROCHE HOLDINGS AG : Jefferies keeps its Buy rating
MD
More news
Financials
Sales 2020 62 761 M 65 262 M 65 262 M
Net income 2020 14 985 M 15 582 M 15 582 M
Net cash 2020 2 284 M 2 375 M 2 375 M
P/E ratio 2020 19,0x
Yield 2020 2,83%
Capitalization 284 B 295 B 295 B
EV / Sales 2019
EV / Sales 2020 4,49x
Nbr of Employees 97 735
Free-Float 83,7%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 378,29 CHF
Last Close Price 332,70 CHF
Spread / Highest target 23,2%
Spread / Average Target 13,7%
Spread / Lowest Target -2,31%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG5.96%295 188
JOHNSON & JOHNSON0.90%387 786
MERCK & CO., INC.-12.52%200 817
PFIZER, INC.-9.49%196 974
NOVARTIS AG-9.65%190 248
ABBVIE INC.2.44%159 844